FASEB Offers Recommendations to Improve Research Funding

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Federation of American Societies for Experimental Biology called for a re-examination of the way research is funded in the U.S., in a report detailing the challenges facing researchers and the threats to continued progress in the field.

The report, Sustaining Discovery in Biological and Medical Science: A Framework for Discussion, presents a series of recommendations to alleviate them.

Shortfalls in federal funding and rising regulatory costs have constrained research budgets, while at the same time, scientific opportunities have expanded and more individuals are seeking funding, the report says. These opposing trends have resulted in an increasingly unstable research enterprise, delaying scientific discovery.

FASEB’s recommendations fall into three categories:

  • Increased advocacy for predictable, sustainable growth in research budgets while striving to make optimal use of existing resources
  • Re-examination of the way research is funded, making certain that we provide incentives to encourage the best science and reduce the amount of time spent seeking funding, and
  • Improved preparation and utilization of the workforce.

“After adjusting for inflation, the federal investment in the life science has declined by more than 20 percent since 2003,” the report says. “Insufficient funding—along with increased regulatory burden and budgetary uncertainty—is a growing obstacle to future advancement.” FASEB recommends that, due to this budget uncertainty, federal research agencies should be able to carry over their budgets into the following fiscal year.

The organization also called for a reduction of the time spent preparing and reviewing grant applications, and that sponsors should consider extending the duration of investigator-initiated awards to decrease the amount of effort spent on competing for funding.

The report is available on FASEB’s website.

YOU MAY BE INTERESTED IN

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login